The Genomic Landscapes of Human Breast and Colorectal Cancers

  title={The Genomic Landscapes of Human Breast and Colorectal Cancers},
  author={Laura D. Wood and D. Williams Parsons and Siân Jones and Jimmy Lin and Tobias Sj{\"o}blom and Rebecca J. Leary and Dong Shen and Simina Maria Boca and Thomas D. Barber and Janine Ptak and Natalie Silliman and Steve Szabo and Zolt{\'a}n Dezső and Vadim Ustyanksky and Tatiana Nikolskaya and Yuri Nikolsky and Rachel Karchin and Paul Alexander Wilson and Joshua S. Kaminker and Zemin Zhang and Randal L. Croshaw and Joseph E. Willis and Dawn M. Dawson and Michail V. Shipitsin and James K. V. Willson and Saraswati Sukumar and Kornelia Polyak and Ben Ho Park and Charit L Pethiyagoda and P. V. Krishna Pant and Dennis Ballinger and Andrew B. Sparks and James Hartigan and Douglas R Smith and Erick Suh and Nickolas Papadopoulos and Phillip Buckhaults and Sanford D. Markowitz and Giovanni Parmigiani and Kenneth W. Kinzler and Victor E. Velculescu and Bert Vogelstein},
  pages={1108 - 1113}
Human cancer is caused by the accumulation of mutations in oncogenes and tumor suppressor genes. To catalog the genetic changes that occur during tumorigenesis, we isolated DNA from 11 breast and 11 colorectal tumors and determined the sequences of the genes in the Reference Sequence database in these samples. Based on analysis of exons representing 20,857 transcripts from 18,191 genes, we conclude that the genomic landscapes of breast and colorectal cancers are composed of a handful of… 

Mutational profiling of cancer candidate genes in glioblastoma, melanoma and pancreatic carcinoma reveals a snapshot of their genomic landscapes

The mutational profiles of 27 ‘hill’ CAN genes in glioblastoma, melanoma and pancreatic carcinoma are evaluated by sequencing the exons previously found mutated by Wood and colleagues, suggesting that ‘ hill’ type CAN genes are not frequently shared by different tumor types and that their mutation patterns are tissue specific.

Mutation Mechanisms of Human Breast Cancer

The results suggest that 2-14 mutations in the genome of breast stem cells are required for normal breaststem cells to become a malignant cell, and 3 gene mutations are most likely to occur in the development of female breast cancer.

Mutational spectra of human cancer

Evidence that can be used to reconstruct the etiology of human cancers from mutations found in tumors is summarized to produce mutational spectra similar to those in TP53 but have unveiled a previously unrecognized common G to C transversion mutation signature at GpA dinucleotides in breast cancers and several other cancers.

Sequence Mutations of Genes Pertaining to Malignancy in Cancer

This review will describe sequence mutations of several cancer-related genes and discuss their functional implications in cancer, and introduce the on-line resources for accessing and analyzing sequence mutations in cancer.

Defining the blueprint of the cancer genome.

Systematic sequencing studies have been performed on gene families involved in signal transduction in several tumor types, and have been extended to include the majority of protein-coding genes in breast and colorectal cancers, and identified new genes and pathways that had not been linked previously to human cancer.

Our changing view of the genomic landscape of cancer

  • D. Bell
  • Biology
    The Journal of pathology
  • 2010
A historical perspective on the identification of somatic alterations in the pre‐ and post‐genomic eras is provided, with a particular emphasis on recent pioneering studies that have provided unprecedented insights into the genomic landscape of human cancer.

Mutation spectrum in human colorectal cancers and potential functional relevance

Evidence of the utility of RNA-Seq in mutation screening in cancer studies is provided, and a list of candidate genes for future colorectal cancer diagnosis and treatment is suggested.

Mutational heterogeneity in human cancers: origin and consequences.

Detailed information is gathered on the nucleotide sequence changes in a number of human cancers to help identify key rate-limiting genes for tumor growth that could serve as potential targets for directed therapies.

Deciphering and Targeting Oncogenic Mutations and Pathways in Breast Cancer.

The importance of administering investigational targeted therapies, or off-label use of approved targeted drugs, in the context of a formal clinical trial or registry programs to facilitate learning about the clinical utility of tumor target profiling is emphasized.

Biology of Human Tumors ExomeSequencingReveals AMER 1 asaFrequently Mutated Gene in Colorectal Cancer

Variants resulting in early stop codons in the AMER1 (also known as FAM123B or WTX) gene emerged as recurrent mutations in colorectal cancer, exhibiting a characteristic phenotype.




Recently, many cellular oncogenes were identified in human cancerous cells by the DNA transfection method, some of which were found to contain sequences related with already known viral oncogenees.


Investigations compel the view that the ratio of the vital capacity to the body length, trunk length, chest circumference, surface area or weight or any combination of these measurements, is too variable to admit of any workable standard or normal value.

J. Comput. Chem

  • J. Comput. Chem
  • 2004

Structural models of mutants identified in colorectal cancers

    Cancer Res

    • Cancer Res
    • 2004

    Nat. Genet

    • Nat. Genet
    • 1999

    PLoS Comput. Biol

    • PLoS Comput. Biol
    • 2007

    Nat. Rev. Cancer

    • Nat. Rev. Cancer
    • 2004

    Nucleic Acids Res

    • Nucleic Acids Res
    • 2007